Eylea

Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.[2][3] It is an inhibitor of vascular endothelial growth factor (VEGF).[4][5] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Interactions 5 Mechanism of action ... [wikipedia]